M

MaxCyte Inc
NASDAQ:MXCT

Watchlist Manager
MaxCyte Inc
NASDAQ:MXCT
Watchlist
Price: 3.56 USD -0.56% Market Closed
Market Cap: 374.9m USD
Have any thoughts about
MaxCyte Inc?
Write Note

Intrinsic Value

MXCT's intrinsic value estimate is unreliable because it is based only on its multiples and doesn't use a DCF valuation.

The intrinsic value of one MXCT stock under the Base Case scenario is 3.48 USD. Compared to the current market price of 3.56 USD, MaxCyte Inc is Overvalued by 2%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

MXCT Intrinsic Value
3.48 USD
Overvaluation 2%
Intrinsic Value
Price
M
Worst Case
Base Case
Best Case

Valuation Backtest
MaxCyte Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.

Start backtest now and learn if your stock is truly undervalued or overvalued!

Run Backtest
Backtest Conclusion
Very Attractive
Current Valuation
+45%
Avg Valuation
-12%
Worst Valuation
-49%
Best Valuation
+45%

Stock is trading at its lowest valuation over the past 5 years.

Backtest Example
Register to View Results
Register to View Results

To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.

Backtest Unavailable

The backtest for MXCT cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.

Backtest In Progress...
Backtest In Progress...
How do you feel about MXCT?
Bearish
Neutral
Bullish

Fundamental Analysis

Risks & Rewards

 

 

 

 

View All Risks & Rewards
Company Quality
No Indicators Selected
Select Indicators

Select up to 3 indicators:

Insider Trading
0-3
Months
0-6
Months
0-12
Months
0-36
Months
No Periods Selected
Select Periods

Select up to 2 periods:

Notes
AI Assistant
AI Assistant
Ask me anything about MaxCyte Inc

Provide an overview of the primary business activities
of MaxCyte Inc.

What unique competitive advantages
does MaxCyte Inc hold over its rivals?

What risks and challenges
does MaxCyte Inc face in the near future?

Summarize the latest earnings call
of MaxCyte Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for MaxCyte Inc.

Provide P/S
for MaxCyte Inc.

Provide P/E
for MaxCyte Inc.

Provide P/OCF
for MaxCyte Inc.

Provide P/FCFE
for MaxCyte Inc.

Provide P/B
for MaxCyte Inc.

Provide EV/S
for MaxCyte Inc.

Provide EV/GP
for MaxCyte Inc.

Provide EV/EBITDA
for MaxCyte Inc.

Provide EV/EBIT
for MaxCyte Inc.

Provide EV/OCF
for MaxCyte Inc.

Provide EV/FCFF
for MaxCyte Inc.

Provide EV/IC
for MaxCyte Inc.

Show me price targets
for MaxCyte Inc made by professional analysts.

What are the Revenue projections
for MaxCyte Inc?

How accurate were the past Revenue estimates
for MaxCyte Inc?

What are the Net Income projections
for MaxCyte Inc?

How accurate were the past Net Income estimates
for MaxCyte Inc?

What are the EPS projections
for MaxCyte Inc?

How accurate were the past EPS estimates
for MaxCyte Inc?

What are the EBIT projections
for MaxCyte Inc?

How accurate were the past EBIT estimates
for MaxCyte Inc?

Compare the revenue forecasts
for MaxCyte Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of MaxCyte Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of MaxCyte Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of MaxCyte Inc compared to its peers.

Compare the P/E ratios
of MaxCyte Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing MaxCyte Inc with its peers.

Analyze the financial leverage
of MaxCyte Inc compared to its main competitors.

Show all profitability ratios
for MaxCyte Inc.

Provide ROE
for MaxCyte Inc.

Provide ROA
for MaxCyte Inc.

Provide ROIC
for MaxCyte Inc.

Provide ROCE
for MaxCyte Inc.

Provide Gross Margin
for MaxCyte Inc.

Provide Operating Margin
for MaxCyte Inc.

Provide Net Margin
for MaxCyte Inc.

Provide FCF Margin
for MaxCyte Inc.

Show all solvency ratios
for MaxCyte Inc.

Provide D/E Ratio
for MaxCyte Inc.

Provide D/A Ratio
for MaxCyte Inc.

Provide Interest Coverage Ratio
for MaxCyte Inc.

Provide Altman Z-Score Ratio
for MaxCyte Inc.

Provide Quick Ratio
for MaxCyte Inc.

Provide Current Ratio
for MaxCyte Inc.

Provide Cash Ratio
for MaxCyte Inc.

What is the historical Revenue growth
over the last 5 years for MaxCyte Inc?

What is the historical Net Income growth
over the last 5 years for MaxCyte Inc?

What is the current Free Cash Flow
of MaxCyte Inc?

Discuss the annual earnings per share (EPS)
trend over the past five years for MaxCyte Inc.

Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
MaxCyte Inc

Current Assets 172.9m
Cash & Short-Term Investments 153.8m
Receivables 4.6m
Other Current Assets 14.5m
Non-Current Assets 75.7m
Long-Term Investments 42.8m
PP&E 31.9m
Other Non-Current Assets 1.1m
Current Liabilities 17.6m
Accounts Payable 1.9m
Accrued Liabilities 9.1m
Other Current Liabilities 6.7m
Non-Current Liabilities 17.7m
Other Non-Current Liabilities 17.7m
Efficiency

Earnings Waterfall
MaxCyte Inc

Revenue
45.6m USD
Cost of Revenue
-6.4m USD
Gross Profit
39.2m USD
Operating Expenses
-85.6m USD
Operating Income
-46.4m USD
Other Expenses
10.7m USD
Net Income
-35.7m USD

Free Cash Flow Analysis
MaxCyte Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
Fundamental Scores

MXCT Profitability Score
Profitability Due Diligence

MaxCyte Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
Positive Revenue Growth Forecast
Positive 1-Year Revenue Growth
Negative ROE
27/100
Profitability
Score

MaxCyte Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

MXCT Solvency Score
Solvency Due Diligence

MaxCyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Low D/E
81/100
Solvency
Score

MaxCyte Inc's solvency score is 81/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

MXCT Price Targets Summary
MaxCyte Inc

Wall Street analysts forecast MXCT stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for MXCT is 9.44 USD with a low forecast of 7.07 USD and a high forecast of 11.55 USD.

Lowest
Price Target
7.07 USD
99% Upside
Average
Price Target
9.44 USD
165% Upside
Highest
Price Target
11.55 USD
224% Upside
View Analyst Estimates
View Analyst Estimates
Want to learn more about Wall St estimates for MXCT?

Click here to dive deeper.

Dividends

MaxCyte Inc
does not pay dividends
Shareholder Yield

Current shareholder yield for MXCT is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Profile

MaxCyte Inc

Country

United States of America

Industry

Life Sciences Tools & Services

Market Cap

374.9m USD

Dividend Yield

0%

Description

MaxCyte, Inc. engages in the development and licensing of cell-engineering technologies to pharmaceutical and biotechnology companies. The company is headquartered in Gaithersburg, Maryland. The company went IPO on 2016-03-29. The firm is focused on providing enabling platform technologies to advance cell-based research and development, as well as next-generation cell therapeutic discovery, development and commercialization. The firm has developed and commercialized its Flow Electroporation platform, which facilitates complex engineering of a variety of cells. Its ExPERT platform is based on its Flow Electroporation technology, which has been designed to address the cell therapy market and can be utilized across the continuum of the high-growth cell therapy sector, from discovery and development through commercialization of next-generation, cell-based medicines. Its ExPERT platform consists of three instruments, which are known as the ATx, STx and GTx. The firm has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.

Contact

MARYLAND
Gaithersburg
22 Firstfield Road, Suite 250
+13015175556.0
www.maxcyte.com

IPO

2016-03-29

Employees

-

Officers

President, CEO & Executive Director
Mr. Maher Masoud
Founder
Mr. Douglas Arthur Doerfler
Chief Financial Officer
Mr. Douglas J. Swirsky CFA, CPA
Senior Vice President of Operations
Mr. Jay Gelfman
Executive Vice President of Administration
Mr. Ronald Evan Holtz CPA, Ph.D.
Senior Vice President, General Counsel & Corporate Secretary
Mr. David Sandoval
Show More
Executive Vice President of Global Sales
Mr. Thomas Michael Ross
Vice President of Corporate Development
Mr. Jack Horgan
Senior Vice President of Human Resources
Ms. Jill Mayer
Consultant
Dr. J. Stark Thompson Ph.D.
Show Less

See Also

Discover More
What is the Intrinsic Value of one MXCT stock?

The intrinsic value of one MXCT stock under the Base Case scenario is 3.48 USD.

Is MXCT stock undervalued or overvalued?

Compared to the current market price of 3.56 USD, MaxCyte Inc is Overvalued by 2%.

Back to Top